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Time to Cardioversion After Catheter Ablation. Introduction: It is unclear whether early restora-
tion of sinus rhythm in patients with persistent atrial arrhythmias after catheter ablation of atrial fibrillation
(AF) facilitates reverse atrial remodeling and promotes long-term maintenance of sinus rhythm. The pur-
pose of this study was to determine the relationship between the time to restoration of sinus rhythm after
a recurrence of an atrial arrhythmia and long-term maintenance of sinus rhythm after radiofrequency
catheter ablation of AF.
Methods and Results: Radiofrequency catheter ablation was performed in 384 consecutive patients (age
60 ± 9 years) for paroxysmal (215 patients) or persistent AF (169 patients). Transthoracic cardioversion
was performed in all 93 patients (24%) who presented with a persistent atrial arrhythmia: AF (n = 74) or
atrial flutter (n = 19) at a mean of 51 ± 53 days from the recurrence of atrial arrhythmia and 88 ± 72 days
from the ablation procedure. At a mean of 16 ± 10 months after the ablation procedure, 25 of 93 patients
(27%) who underwent cardioversion were in sinus rhythm without antiarrhythmic therapy. Among the 46
patients who underwent cardioversion at ≤30 days after the recurrence, 23 (50%) were in sinus rhythm
without antiarrhythmic therapy. On multivariate analysis of clinical variables, time to cardioversion within
30 days after the onset of atrial arrhythmia was the only independent predictor of maintenance of sinus
rhythm in the absence of antiarrhythmic drug therapy after a single ablation procedure (OR 22.5; 95% CI
4.87–103.88, P < 0.001).
Conclusion: Freedom from AF/flutter is achieved in approximately 50% of patients who undergo car-
dioversion within 30 days of a persistent atrial arrhythmia after catheter ablation of AF. (J Cardiovasc
Electrophysiol, Vol. 20, pp. 1321-1325, December 2009)
atrial fibrillation, catheter ablation, cardioversion, recurrence
Introduction
Early recurrences of atrial arrhythmias within 3 months
after catheter ablation of atrial fibrillation (AF) may be tran-
sient in 30–50% of patients and may not necessarily pre-
dict long-term clinical outcome.1,2 However, it is not clear
whether early restoration of sinus rhythm by cardioversion
after a recurrence is associated with an improvement in clin-
ical outcome after catheter ablation of AF.
The purpose of this study was to determine the relation-
ship between the time to restoration of sinus rhythm after
a recurrence of an atrial arrhythmia and long-term mainte-
nance of sinus rhythm after radiofrequency catheter ablation
of AF.
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The subjects of this retrospective study were 93 consecu-
tive patients who underwent transthoracic cardioversion for
a persistent atrial arrhythmia. These patients were selected
from a pool of 384 consecutive patients who underwent ra-
diofrequency catheter ablation to eliminate paroxysmal (215
patients) or persistent (169 patients) AF. A persistent (>24
hours) episode of atrial flutter or AF was considered as an
atrial arrhythmia in this study. The clinical characteristics of
patients are shown in Table 1. Patients who have had >1 prior
ablation procedures to eliminate AF were excluded from this
study.
Electrophysiologic Study and Radiofrequency Catheter
Ablation
All patients provided written informed consent. An elec-
trophysiologic study was performed in the fasting state. All
antiarrhythmic drugs except amiodarone were discontinued
at least 4–5 half-lives before the procedure. Amiodarone was
discontinued 8 weeks before the procedure. Vascular access
was obtained through a femoral vein. A quadripolar catheter
was placed in the coronary sinus for recording electrograms
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TABLE 1




(n = 93) (n = 25) (n = 68)
Ages (years) 60 ± 9 59 ± 9 60 ± 9
Male 72 (77) 20 (80) 52 (76)
Paroxysmal AF 52 (56) 10 (42) 42 (61)
Duration of AF (months) 76 ± 61 79 ± 64 75 ± 60
Ejection fraction (%) 54 ± 9 55 ± 10 54 ± 9
Left atrial size (mm) 45 ± 7 45 ± 7 45 ± 7
Coronary disease 12 (13) 2 (8) 10 (15)
Hypertension 55 (59) 15 (60) 40 (59)
Hyperlipidemia 48 (52) 13 (52) 35 (52)
Diabetes mellitus 15 (16) 6 (24) 9 (13)
Sleep apnea 14 (15) 5 (20) 9 (13)
Beta-blocker therapy 67 (72) 18 (72) 49 (72)
Calcium channel blocker
therapy
28 (30) 6 (24) 22 (32)
ACE inhibitor 26 (28) 9 (36) 17 (25)
ARB 6 (7) 1 (4) 5 (7)
Digoxin 24 (26) 8 (32) 16 (23)
Statin 41 (44) 13 (52) 28 (41)
Amiodarone postablation 20 (22) 6 (24) 14 (21)




37 (40) 8 (32) 29 (43)
Time to recurrence after
ablation (days)
37 ± 49 37 ± 53 37 ± 47
Time to cardioversion
after recurrence (days)
51 ± 53 11 ± 15 66 ± 55
Data are expressed as mean ± SD. ACE = angiotensin-converting enzyme;
ARB = angiotensin receptor blocker; CI = confidence interval; OR = odds
ratio.
and for atrial pacing. After transseptal access, systemic anti-
coagulation was achieved with intravenous heparin to main-
tain an activated clotting time of 300–350 seconds. A decap-
olar ring catheter (Lasso, Biosense Webster, Diamond Bar,
CA, USA) was used to map pulmonary veins (PVs). Bipolar
electrograms were displayed and recorded at filter settings of
30 to 500 Hz during the procedure (EPMed Systems, West
Berlin, NJ, USA).
All patients underwent antral PV isolation to isolate the
PVs using an open-irrigation, 3.5-mm-tip deflectable catheter
(Thermocool, Biosense Webster). If AF still persisted after
antral pulmonary vein isolation (APVI), complex fraction-
ated atrial electrograms in the left atrium and coronary sinus
were targeted until AF terminated or all identifiable target
sites were eliminated, at the discretion of the operator.
All patients were observed with electrocardiographic
monitoring during an overnight hospital stay after the ab-
lation. Patients were discharged home taking warfarin and
low-molecular-weight heparin as a bridge to therapeutic an-
ticoagulation.
Study Protocol
The study protocol was approved by the Institutional Re-
view Board. All patients were seen in an outpatient clinic
3 months after the procedure and every 3–6 months there-
after. Patients were provided with an auto-triggered event
monitor for 30 days, ≥3 months after the procedure. Patients
were also asked to call whenever they experienced symptoms
Figure 1. Time to recurrent atrial arrhythmia after catheter ablation. Cu-
mulative proportion of patients who developed persistent AF or atrial flutter
after catheter ablation and time to recurrence (days) are shown.
suggestive of an arrhythmia. In addition, patients were called
periodically to assess their symptomatic status. Recurrent
atrial arrhythmias within 3 months after the ablation were
captured primarily based on the symptoms reported by the
patient or evidence of an arrhythmia on an electrocardiogram.
The time of recurrence of atrial arrhythmias was determined
by the first occurrence of patient-reported symptoms after
the ablation. In the 2 patients who were asymptomatic, the
first documented episode of an atrial arrhythmia on an event
monitor indicated the time of recurrence. Patients with re-
current atrial arrhythmias were treated with a class I or III
antiarrhythmic drug in addition to a beta-blocker and/or cal-
cium channel blocker for ventricular rate control. Electrical
cardioversion was performed in all of the patients with per-
sistent atrial arrhythmias. Antiarrhythmic drug therapy was
discontinued within 3 months after the cardioversion in all
patients who had no further episodes of atrial arrhythmias.
Those patients with recurrent arrhythmias despite drug ther-
apy were offered a repeat ablation. All asymptomatic patients
were provided with a 30-day auto-triggered event monitor 3
months after the cardioversion.
Statistical Analysis
Continuous variables are expressed as mean ± 1 standard
deviation and were compared using the t-test. Categorical
variables were compared by the chi-square analysis or the
Fisher exact test as appropriate. Logistic regression analysis
was performed to determine the predictors of freedom from
atrial arrhythmias. All analyses were performed using SPSS
(15.0) for Windows (SPSS Inc., Chicago, IL, USA). A P <
0.05 indicated statistical significance.
Results
Recurrence of Atrial Arrhythmias After Catheter Ablation
Among the 384 patients, 93 (24%) experienced a persis-
tent recurrent atrial arrhythmia: AF (74 patients) or atrial
flutter (19 patients), at a mean of 37 ± 49 days after the
ablation procedure. There was no significant difference in
the time to recurrence of AF, 36 ± 50 days, and atrial flut-
ter, 40 ± 44 days, (P = 0.73). Among the 93 patients, the
first recurrence occurred within 24 hours in 6%, 1 week in
37%, 1 month in 66%, and 3 months in 88% of the patients
(Fig. 1).
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TABLE 2
Univariate Analysis of Clinical Characteristics in Patients With and
Without Recurrent Atrial Arrhythmias After Cardioversion
OR ± 95% CI P Value
Age (years) 0.99 0.94–1.05 0.79
Male 1.75 0.53–5.82 0.36
Paroxysmal AF 0.52 0.21–1.31 0.16
Duration of AF (months) 1.00 0.99–1.01 0.42
Ejection fraction (%) 1.02 0.96–1.07 0.57
Left atrial size (mm) 1.01 0.95–1.08 0.76
Coronary disease 1.98 0.40–9.75 0.40
Hypertension 0.95 0.37–2.43 0.92
Hyperlipidemia 0.98 0.39–2.45 0.96
Diabetes mellitus 0.48 0.15–1.53 0.22
Sleep apnea 2.34 0.28–19.69 0.43




ACE inhibitor 0.59 0.22–1.59 0.29
ARB 1.91 0.21–17.16 0.57
Digoxin 0.65 0.24–1.80 0.41
Statin 0.65 0.26–1.62 0.35
Amiodarone postablation 1.04 0.33–3.25 0.95










0.96 0.94–0.98 < 0.001
Data are expressed as mean ± SD. ACE = angiotensin-converting enzyme;
AF = atrial fibrillation; ARB = angiotensin receptor blocker; CI = confi-
dence interval; OR = odds ratio.
Time to Cardioversion
The mean time to electrical cardioversion was 88 ± 72
days after the ablation procedure. The mean interval from
the first recurrence of atrial arrhythmia to cardioversion was
51 ± 53 days. Among the 93 patients, cardioversion was
performed within 1 week in 34%, 1 month in 49%, and
3 months in 75%.
At the time of cardioversion, 48 of 93 patients (52%)
were being treated with an antiarrhythmic drug: class IC in
20% and class III in 32% (sotalol in 10% and amiodarone
in 22%). All antiarrhythmic drug therapy was discontinued
within 3 months after cardioversion.
Clinical Outcome After Cardioversion
At a mean follow-up of 16 ± 10 months after a single ab-
lation procedure and 15 ± 10 months after cardioversion, 25
of 93 patients (27%) were free of recurrent atrial arrhythmias
TABLE 3
Time from Arrhythmia Recurrence to Cardioversion and Probability of Maintaining Sinus Rhythm
Time to No Recurrent
Cardioversion After Total Recurrence Arrhythmias
Recurrence (Days) (n = 93) (n = 25) (n = 68) OR ± 95% CI P Value
0–7 32 16 16 22.5 4.65–108.89 <0.001
8–30 14 7 7 22.5 3.86–131.00 0.001
≥31 47 2 45 1.00 – –
CI = confidence interval; OR = odds ratio.
in the absence of antiarrhythmic drug therapy. Sinus rhythm
was maintained in 22 of 74 (30%) patients who underwent
cardioversion for persistent AF and in 3 of 19 (16%) patients
who underwent cardioversion for persistent atrial flutter
(P = 0.26).
Time to Cardioversion and Clinical Outcome
The interval from atrial arrhythmia recurrence to car-
dioversion was shorter among patients who remained in sinus
rhythm after the cardioversion, 11 ± 15 days, than patients
who had recurrent atrial arrhythmias, 65 ± 55 days (P <
0.001, Table 2). Patients who underwent cardioversion within
30 days after a recurrence were more likely to remain in si-
nus rhythm than patients who were cardioverted after 30 days
(OR 22.5, 95% CI 4.87–103.88; P < 0.001, Table 3). The
proportion of patients who remained in sinus rhythm was
similar whether cardioversion was performed within 1 week
(16 of 32, 50%) or 1 week to 1 month (7 of 14, 50%) after
the recurrence of an atrial arrhythmia (Table 3). However,
only 2 of 47 patients (4%) who underwent cardioversion >1
month after the recurrence remained in sinus rhythm (P <
0.001, Fig. 2). Among all other clinical variables, there were
no univariate predictors of freedom from atrial arrhythmias
after cardioversion (Table 2).
Multivariate Analysis
Multivariate analysis that included age, gender, duration
of AF, whether AF was paroxysmal or persistent, whether
recurrent atrial arrhythmia was AF or atrial flutter, left atrial
size, left ventricular ejection fraction, ablation of complex
fractionated atrial electrograms, time to recurrence after ab-
lation, time to cardioversion after recurrence of arrhythmia,
and concomitant antiarrhythmic drug therapy, demonstrated
that the time from atrial arrhythmia recurrence to cardiover-
sion was the only independent predictor of maintenance of
sinus rhythm in the absence of antiarrhythmic drug therapy
after a single ablation procedure (P < 0.001).
Discussion
Main Findings
The main finding of this study is that after radiofrequency
catheter ablation of AF, the restoration of sinus rhythm within
30 days of the onset of a persistent recurrent atrial arrhythmia
is associated with a higher probability of long-term mainte-
nance of sinus rhythm, regardless of when the arrhythmia first
recurs after the ablation procedure. Freedom from recurrent
atrial arrhythmias is achieved without additional catheter ab-
lation in approximately 50% of patients who undergo early
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Figure 2. Freedom from recurrent atrial arrhythmias. The proportion of
patients who underwent cardioversion in ≤30 days (solid line) and >30 days
(dashed line) of recurrent persistent atrial arrhythmias and who remained
in sinus rhythm without antiarrhythmic drug therapy after a single ablation
procedure is shown.
cardioversion. However, if cardioversion is postponed for
>30 days, virtually all patients will require a second ablation
procedure.
These observations suggest that early restoration of sinus
rhythm after catheter ablation may prevent progressive elec-
troanatomical remodeling and may facilitate the long-term
maintenance of sinus rhythm.
Recurrence of Atrial Arrhythmias After Catheter Ablation
As extensively reported previously, a majority of atrial ar-
rhythmias occur within several weeks after catheter ablation
of AF.2,3 Recurrences also may occur late after ablation, how-
ever, at a much lower rate of <5–10% per year.3,4 Although
patients who experience early recurrence of AF or atrial flut-
ter are more likely to have recurrent AF and/or atrial flutter
during long-term follow-up, approximately 30–50% of pa-
tients with an early recurrence may later remain free from
recurrent atrial arrhythmias.1,2,5,6 Therefore, monitoring of
the rhythm rather than routine early repeat ablation may be
appropriate in these patients.
It has been suggested that early recurrences may be due
to an inflammatory response or recovery of PV conduction,
and that late recurrences of AF are more likely to result from
emergence of new foci and mechanisms of AF in addition
to recovery of conduction over previously ablated sites.3,4,6
Therefore, it may be argued that the time of recurrence of
an atrial arrhythmia after ablation rather than the time to
cardioversion after the recurrence affects the probability of
maintaining sinus rhythm after the cardioversion. However,
the findings of this study suggest that even when adjusted
for the time of recurrence, time to cardioversion is the only
independent predictor of a successful long-term outcome.
Time to Cardioversion: Early Restoration of Sinus
Rhythm After Catheter Ablation
Patients who underwent cardioversion within 1 month of
a recurrence of an atrial arrhythmia were >20 times more
likely to remain in sinus rhythm than patients who underwent
cardioversion later, regardless of when the arrhythmia first
recurred or whether concomitant antiarrhythmic drug therapy
was utilized. The clinical outcome was similar for both AF
and atrial flutter, although the 2 are mechanistically distinct
arrhythmias. It may be that it is the rapid atrial rate rather
than the type of atrial arrhythmia that is critical in progressive
atrial remodeling.7-9
Early restoration of sinus rhythm is likely to prevent pro-
gressive atrial electroanatomical remodeling and facilitate
long-term maintenance of sinus rhythm, consistent with the
finding of the first experimental study that suggested that
“AF begets AF.”8 It has been also recognized that remodeling
within the PVs occurs in response to atrial tachyarrhythmias,
both in experimental models and human subjects.7,10 The
probability of maintaining sinus rhythm after cardioversion
in this study was independent of timing as long as cardiover-
sion was performed within 1 month of the onset of the atrial
arrhythmia. This suggests that sufficient remodeling capable
of perpetuating AF develops only after 1 month of rapid atrial
activation.
Pulmonary vein arrhythmogenicity may be caused by trig-
gered activity.11-13 It is recognized that continual stimulation
of the PVs at a high frequency may maintain PV arrhyth-
mogenicity.14,15 Therefore, the early interruption of atrial re-
modeling and mechanisms capable of perpetuating AF may
further inhibit PV arrhythmogenicity and facilitate long-term
maintenance of AF.
Consistent with the findings of this study, a prior ret-
rospective analysis in patients with AF demonstrated that
early repeat ablation in patients who have recurrent AF after
catheter ablation was associated with a higher probability
of long-term maintenance of sinus rhythm, however, with a
significantly higher repeat ablation rate per patient (2.5/pa-
tient).5 It may be that if sinus rhythm was restored by early
cardioversion rather than repeat ablation, half of the repeat
procedures could have been avoided in that study.
Limitations
A limitation of this study is that the timing of the onset
of atrial arrhythmias was based on the patient’s report of
symptoms or the first documented episode in asymptomatic
patients. There may have been delays in the recognition
of asymptomatic recurrences. However, only 2 patients in
this study were completely asymptomatic during recurrent
episodes of atrial arrhythmias. Due to intense clinical follow-
up, any delay in recognition of an arrhythmia would not have
been any longer than 1–2 months in this study.
Another limitation is that this was not a prospective, ran-
domized study. This study provides justification for a large-
scale randomized study to assess the role of early cardiover-
sion in patients with recurrent atrial arrhythmias after catheter
ablation.
Clinical Implications
The findings of this study underscore the importance
of close surveillance of rhythm status after radiofrequency
catheter ablation of AF. The early restoration of sinus rhythm
within 1 month of the onset of an atrial arrhythmia may obvi-
ate the need for repeat ablation procedures in approximately
50% of the patients with persistent recurrent atrial arrhyth-
mias after catheter ablation.
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